Eloxx Pharmaceuticals (ELOX)

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates (designed to be eukaryotic ribosomal selective glycosides) that are formulated to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxx's lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx's preclinical candidate pool consists of a library of novel drug candidates designed to be eukaryotic ribosomal selective glycosides identified based on read-through potential. Eloxx also has preclinical programs focused on kidney diseases including autosomal dominant polycystic kidney disease, as well as rare ocular genetic disorders. Eloxx is headquartered in Waltham, MA, with operations in Rehovot, Israel and Morristown, NJ.

Company profile

Gregory Williams
Fiscal year end
Former names
Eloxx Pharmaceuticals Ltd. • Eloxx Pharmaceuticals (AUS) Pty Ltd. ...
IRS number

ELOX stock data

Analyst ratings and price targets

Last 3 months

Investment data

Data from SEC filings
Securities sold
Number of investors


6 May 22
2 Jul 22
31 Dec 22
Quarter (USD) Mar 22 Dec 21 Sep 21 Jun 21
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 40.07M 40.07M 40.07M 40.07M 40.07M 40.07M
Cash burn (monthly) 834K (no burn) 3.65M 5.71M 3.16M 3.07M
Cash used (since last report) 2.56M n/a 11.19M 17.52M 9.7M 9.4M
Cash remaining 37.51M n/a 28.87M 22.55M 30.36M 30.66M
Runway (months of cash) 45.0 n/a 7.9 3.9 9.6 10.0

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
15 Jun 22 Avnur Zafrira Stock Options Common Stock Grant Acquire A No No 0.26 20,000 5.2K 20,000
15 Jun 22 Kariv Tomer Stock Options Common Stock Grant Acquire A No No 0.26 20,000 5.2K 20,000
15 Jun 22 Rajesh B Parekh Stock Options Common Stock Grant Acquire A No No 0.26 20,000 5.2K 20,000
15 Jun 22 Ran Nussbaum Stock Options Common Stock Grant Acquire A No No 0.26 20,000 5.2K 20,000
15 Jun 22 Seehra Jasbir Stock Options Common Stock Grant Acquire A No No 0.26 20,000 5.2K 20,000
13F holders Current Prev Q Change
Total holders 0 0
Opened positions 0 0
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares Current Prev Q Change
Total value 0 0
Total shares 0 0
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners Shares Value Change
Largest transactions Shares Bought/sold Change

Financial report summary

  • We depend heavily on the success of our lead product candidate, ELX-02. If ELX-02 fails during development or suffers any material development delays, it may adversely impact the commercial viability of ELX-02 and our business.
  • Preclinical and clinical drug development is a lengthy and expensive process, with an uncertain outcome. Our preclinical and clinical programs may experience delays or may never advance, which would adversely affect ability to obtain regulatory approvals or commercialize our product candidates on a timely basis or at all, which could have an adverse effect on our business.
  • We and our collaborating partners may be subject, directly or indirectly, to federal and state healthcare fraud and abuse and false claims laws and regulations. If we or our collaborating partners are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.
  • Our product candidates, including ELX-02, may cause adverse events or have other properties that could delay or prevent their regulatory approval or limit the scope of any approved label or market acceptance.
  • A Fast Track Designation by the FDA, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process, and does not increase the likelihood that our product candidates will receive marketing approval.
  • The regulatory approval processes of the FDA and comparable regulatory authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.
  • If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell any of our product candidates that obtain regulatory approval, we may be unable to generate any revenue.
  • Even if our product candidates receive regulatory approval, they will be subject to significant post- marketing regulatory requirements and oversight.
  • The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses.
  • Developments by competitors may render our products or technologies obsolete or non-competitive which would have a material adverse effect on our business, results of operations and financial condition.
  • If we are unable to develop and commercialize our product candidates, our business will be adversely affected.
  • Even if we are able to commercialize any product candidate, coverage and adequate reimbursement may not be available or such product candidate may become subject to unfavorable pricing regulations or third-party coverage and reimbursement policies, which would harm our business.
  • Current and future legislation may increase the difficulty and cost for us and any future collaborators to obtain marketing approval of and commercialize our product candidates and affect the prices we, or they, may obtain.
  • We have incurred significant operating losses since our inception and anticipate that we will continue to incur substantial operating losses for the foreseeable future. We may never achieve or maintain profitability.
  • We will need substantial additional funding. If we are unable to raise capital when needed, we would be forced to delay, reduce or eliminate our product development programs or commercialization efforts.
  • Our recurring losses from operations raise substantial doubt regarding our ability to continue as a going concern.
  • Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.
  • We do not intend to pay dividends for the foreseeable future.
  • Our indebtedness and debt service obligations may adversely affect our cash flow.
  • Our stockholders may not realize a benefit from the Zikani Merger commensurate with the ownership dilution they will experience in connection with the Zikani Merger.
  • Our business could be affected by litigation, government investigations and enforcement actions.
  • We could be subject to additional tax liabilities.
  • Our business could be adversely affected by the effects of widespread public health epidemics and other factors beyond our control.
  • We may be subject to numerous and varying privacy and security laws, and our failure to comply could result in penalties and reputational damage, and adversely affect our financial condition and results of operations.
  • Security breaches, cyber-attacks, or other disruptions could expose us to liability and affect our business and reputation.
  • We currently rely, and plan to rely on in the future, third parties to conduct and support our preclinical studies and clinical trials. If these third parties do not properly and successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our product candidates.
  • Our future success depends on our ability to retain key employees, consultants and advisors and to attract, retain and motivate qualified personnel.
  • If we infringe the rights of third parties, we could be prevented from selling products, forced to pay damages and required to defend against litigation which could result in substantial costs and may have a material adverse effect on our business, results of operations and financial condition.
  • We rely on confidentiality agreements that could be breached and may be difficult to enforce which could have a material adverse effect on our business and competitive position.
  • If we cannot meet requirements under our license agreement, we could lose the rights to our product candidates, which could have a material adverse effect on our business.
  • We received Israeli government grants for our research and development activities and programs. The terms of such grants may require us, in the future, to pay royalties and under certain circumstances, penalties in addition to payment of royalties.
  • Our stock price may be volatile, and purchasers of our common stock could incur substantial losses.
  • Maintaining and improving our financial controls and the requirements of being a public company may strain our resources, divert management’s attention and affect our ability to attract and retain qualified board members.
  • Our ability to use our net operating losses to offset future taxable income may be subject to certain limitations.
  • Future sales and issuances of our securities or rights to purchase securities, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause the prices of our securities to fall.
Management Discussion
  • Research and development expenses were $7.9 million for the three months ended March 31, 2022 compared to $4.1 million for the same period in 2021, an increase of $3.8 million. The increase was primarily related to an increase of $1.9 million related to our preclinical activities, an increase of $0.4 million related to clinical trials, an increase of $0.6 million in employee salaries and benefits, an increase of $0.1 million related to stock-based compensation, and an increase of $0.8 million in overhead and infrastructure costs.  
  • General and administrative expenses were $3.1 million for the three months ended March 31, 2022, compared to $4.3 million for the same period in 2021, a decrease of $1.3 million. The decrease was primarily related to a $0.5 million decrease in salaries and other personnel related costs, a $0.5 million decrease in stock-based compensation expense, a decrease of $0.2 million related to external consultant and professional fees, and a decrease of $0.1 million related to overhead and infrastructure costs.
  • We recorded $0.7 million in other expense, net for the three months ended March 31, 2022, compared to $0.3 million for the same period in 2021. The increase in other expense, net, was primarily due to the recognition of $0.3 million of derivative liabilities related to the CFF awards and a $0.1 million increase in interest expense under the Hercules Term Loan (as defined below).

Content analysis

H.S. junior Avg
New words: absorb, ACA, advertising, age, allele, American, Amsterdam, anesthesiology, attain, attaining, bacterial, bid, Biden, branded, bridging, budget, budgetary, calendar, California, cap, capacity, Carlo, CCPA, certified, characterized, Children, CJEU, Colorado, Commissioner, Congressional, consecutive, consent, constitutionality, constrain, conventional, country, CPRA, CRO, cultural, cure, customer, de, deficiency, degradation, delist, delisted, delisting, Department, departure, deploy, disbursed, dismissed, doctor, domestic, draft, EEA, electrical, engineering, enjoined, exceeding, export, faster, fluid, forbearance, forensic, frequency, gap, geographical, grace, grow, handling, highest, hinder, improper, improperly, inconsistent, input, instance, instructed, Instruction, ivacaftor, July, jurisdiction, Justice, Kalydeco, Kingdom, laid, lawfully, levied, light, mandatory, migrated, mission, misuse, monotherapy, Monte, month, move, notify, notifying, November, nurse, obfuscate, oncology, overhead, owed, packaging, Parliament, passed, payer, penalty, permanent, play, post, postpone, postponed, preceding, precluded, predetermined, prescribe, presidential, prioritization, prioritized, procedure, ransomware, recognition, reconsider, recordkeeping, recoup, refinanced, regain, regime, regular, rejection, relaxation, relocation, remediate, replaced, Rescue, revocation, robust, role, rollforward, rolling, routine, safest, scale, scrutiny, segregation, Shield, shut, shutdown, simulation, social, strictly, stringent, substantive, Sunshine, supervision, supervisory, Supreme, surveillance, Switching, Taxpayer, TCJA, teaching, telecommunication, terrorism, theft, tiered, translation, transparency, trend, unannounced, unclear, uncured, undetected, unfounded, uniform, unique, unmet, unobservable, untitled, upfront, user, viral, Virginia, warning, whichever, writing
Removed: accelerated, advice, allocated, allocation, amendment, amortized, announcement, assign, attributable, biosimilar, captioned, chronic, combat, complexity, considerable, contracting, correspondingly, decreasing, diagnosed, diligently, Directive, dosing, education, enact, entry, ERSG, feedback, formally, glycoside, great, Gregory, impeded, implemented, indefinite, injunction, introduction, investigator, Kleijwegt, leading, malfeasance, marketable, Martijn, measurement, minimal, mitigate, national, nephropathic, Noiman, NOL, organizational, performed, PPACA, principally, prohibited, pursuing, put, realignment, reclassification, reclassified, recruited, Rehovot, repeating, resigned, restoration, rulemaking, satisfactorily, seizure, separation, Silvia, slower, spend, spending, studying, substandard, susceptible, updated, vesting